Galena Biopharma (SLS) Earns Daily News Sentiment Rating of 0.28

News headlines about Galena Biopharma (NYSE:SLS) have been trending positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galena Biopharma earned a daily sentiment score of 0.28 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.2934986420708 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

NYSE:SLS traded down $0.51 on Friday, reaching $5.62. 228,770 shares of the company’s stock were exchanged, compared to its average volume of 482,874. Galena Biopharma has a 52 week low of $3.43 and a 52 week high of $19.80.

How to Become a New Pot Stock Millionaire

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Galena Biopharma in a research report on Monday, April 2nd.

ILLEGAL ACTIVITY WARNING: “Galena Biopharma (SLS) Earns Daily News Sentiment Rating of 0.28” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at

About Galena Biopharma

Develop biopharmaceuticals

Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with's FREE daily email newsletter.

Leave a Reply